SG11201603050TA - Methods for treating cancers - Google Patents

Methods for treating cancers

Info

Publication number
SG11201603050TA
SG11201603050TA SG11201603050TA SG11201603050TA SG11201603050TA SG 11201603050T A SG11201603050T A SG 11201603050TA SG 11201603050T A SG11201603050T A SG 11201603050TA SG 11201603050T A SG11201603050T A SG 11201603050TA SG 11201603050T A SG11201603050T A SG 11201603050TA
Authority
SG
Singapore
Prior art keywords
methods
treating cancers
cancers
treating
Prior art date
Application number
SG11201603050TA
Other languages
English (en)
Inventor
Paolo Julie Di
Michael J Hawkins
Jing Hu
Feng Jin
Flordeliza Melchor-Khan
Anita Reddy
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201603050TA publication Critical patent/SG11201603050TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
SG11201603050TA 2013-12-04 2014-12-03 Methods for treating cancers SG11201603050TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911978P 2013-12-04 2013-12-04
PCT/US2014/068423 WO2015084992A1 (fr) 2013-12-04 2014-12-03 Procédés pour le traitement de cancers

Publications (1)

Publication Number Publication Date
SG11201603050TA true SG11201603050TA (en) 2016-05-30

Family

ID=52232435

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603050TA SG11201603050TA (en) 2013-12-04 2014-12-03 Methods for treating cancers

Country Status (15)

Country Link
US (2) US9687492B2 (fr)
EP (1) EP3076976B1 (fr)
JP (1) JP6298539B2 (fr)
KR (2) KR20180002888A (fr)
CN (1) CN105764516A (fr)
AU (1) AU2014360537B2 (fr)
CA (1) CA2932726C (fr)
DK (1) DK3076976T3 (fr)
EA (1) EA201690608A1 (fr)
ES (1) ES2835549T3 (fr)
MX (1) MX2016007311A (fr)
NZ (1) NZ718825A (fr)
PT (1) PT3076976T (fr)
SG (1) SG11201603050TA (fr)
WO (1) WO2015084992A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707798SA (en) 2008-12-08 2017-10-30 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
ES2530449T3 (es) 2010-03-11 2015-03-02 Gilead Connecticut Inc Inhibidores de Syk de imidazopiridinas
EP3027171B1 (fr) 2013-07-30 2020-03-25 Gilead Connecticut, Inc. Formulation d'inhibiteurs de syk
US9657023B2 (en) * 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
US9376441B2 (en) 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
KR20180002888A (ko) 2013-12-04 2018-01-08 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
US20160375019A1 (en) * 2015-04-21 2016-12-29 Gilead Sciences, Inc. Treatment of chronic graft versus host disease with syk inhibitors
EP3512519A1 (fr) * 2016-09-14 2019-07-24 Gilead Sciences, Inc. Inhibiteurs de syk
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
JP2019533711A (ja) * 2016-11-14 2019-11-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非成人のヒトに対する抗ｃｄ３０抗体−薬物コンジュゲートの投与
WO2018195471A1 (fr) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Inhibiteurs de syk en association avec des agents d'hypométhylation
JP6986624B2 (ja) 2017-08-25 2021-12-22 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤の多形体
TW202016316A (zh) * 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
WO2023174948A2 (fr) * 2022-03-14 2023-09-21 TRx Biosciences Limited Compositions possédant une biodisponibilité améliorée d'agents thérapeutiques et leurs utilisations

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
WO1996034866A1 (fr) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Derives de l'imidazo 1,2-a pyridine et de l'imidazo 1,2-a pyridezine et leur utilisation en tant qu'inhibiteurs de la resorption osseuse
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
EP1363702A4 (fr) 2001-01-30 2007-08-22 Cytopia Pty Ltd Procedes d'inhibition de kinases
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
BR0309398A (pt) 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase
WO2004022562A1 (fr) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-arykl-imidazo[1,2-a]pyrazin-8-ylamines, procede de preparation et procede d'utilisation correspondants
JP4845379B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
EP1543008B1 (fr) 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines utilises en tant qu'inhibiteurs de kinase dependant de la cycline
CN1694706A (zh) 2002-09-23 2005-11-09 先灵公司 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (fr) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
WO2005085252A1 (fr) 2004-03-04 2005-09-15 Biofocus Discovery Limited Composes de 1,2-a' pyrazine imidazo interagissant avec les proteines kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1812442A2 (fr) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
RU2008122967A (ru) 2005-11-10 2009-12-20 Шеринг Корпорейшн (US) Имидазопиразины в качестве ингибиторов протеинкиназ
CA2662074A1 (fr) 2006-08-30 2008-03-06 Cellzome Limited Derives de triazole en tant qu'inhibiteurs de kinase
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
LT2716157T (lt) 2008-12-08 2016-09-12 Gilead Connecticut, Inc. Imidazopirazino syk inhibitoriai
SG10201707798SA (en) 2008-12-08 2017-10-30 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
ES2530449T3 (es) * 2010-03-11 2015-03-02 Gilead Connecticut Inc Inhibidores de Syk de imidazopiridinas
WO2013049750A1 (fr) * 2011-09-29 2013-04-04 Trovagene, Inc. Mutations dans sf3b1 et leucémie lymphoïde chronique
US20130338142A1 (en) 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
CA2882134A1 (fr) 2012-08-14 2014-02-20 Gilead Calistoga Llc Polytherapies pour le traitement du cancer
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
EP3027171B1 (fr) 2013-07-30 2020-03-25 Gilead Connecticut, Inc. Formulation d'inhibiteurs de syk
US9376441B2 (en) 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
KR20180002888A (ko) 2013-12-04 2018-01-08 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20160375019A1 (en) 2015-04-21 2016-12-29 Gilead Sciences, Inc. Treatment of chronic graft versus host disease with syk inhibitors

Also Published As

Publication number Publication date
WO2015084992A1 (fr) 2015-06-11
PT3076976T (pt) 2020-12-07
ES2835549T3 (es) 2021-06-22
CA2932726C (fr) 2019-06-04
MX2016007311A (es) 2016-09-07
CA2932726A1 (fr) 2015-06-11
EP3076976A1 (fr) 2016-10-12
US9974792B2 (en) 2018-05-22
EP3076976B1 (fr) 2020-09-02
JP2016538347A (ja) 2016-12-08
CN105764516A (zh) 2016-07-13
DK3076976T3 (da) 2020-12-07
KR20180002888A (ko) 2018-01-08
US20150150881A1 (en) 2015-06-04
EA201690608A1 (ru) 2016-12-30
JP6298539B2 (ja) 2018-03-20
US20170258804A1 (en) 2017-09-14
NZ718825A (en) 2017-10-27
AU2014360537A1 (en) 2016-05-05
US9687492B2 (en) 2017-06-27
KR20160090903A (ko) 2016-08-01
AU2014360537B2 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
SG11201603050TA (en) Methods for treating cancers
HK1220155A1 (zh) 治療癌症的方法
IL245281A0 (en) Methods and preparations for the treatment of cancer
EP3049442A4 (fr) Méthodes de traitement de cancers hématologiques
EP2968343A4 (fr) Polythérapie pour traiter un cancer
GB201318983D0 (en) Radiotherapy apparatus
GB201420103D0 (en) Treating particles
HK1213817A1 (zh) 治療癌症的方法
HK1225647A1 (zh) 用於治療癌症的組合物和方法
HK1219489A1 (zh) 治療結腸直腸癌的方法
PL3054959T3 (pl) Sposoby leczenia złośliwych nowotworów zwłóknieniowych
HK1215164A1 (zh) 處理方法
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
IL245037B (en) Treatment for pancreatic cancer
HK1219513A1 (zh) 治療癌症的方法
HK1223547A1 (zh) 癌症治療方法
HUE048625T2 (hu) Módszer rák kezelésére
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
EP2941270A4 (fr) Procédés pour traiter l'inflammation
GB201402997D0 (en) Improved apparatus
PL2836176T3 (pl) Sposób leczenia starczowzroczności
HK1202453A1 (en) Therapeutic composition for treating cancers
EP2971044A4 (fr) Compositions et méthodes pour le traitement du cancer
GB201321531D0 (en) Treatment for cancers